Robinhood's new top lawyer, a former SEC commissioner, could help the firm shed its scrappy roots

Quick Take

  • Recently appointed as CLO of Robinhood, former SEC commissioner Dan Gallagher could help shake off the broker’s scrappy roots
  • The former SEC commissioner navigated a media firestorm as the chief legal officer of EpiPen maker Mylan
  • Gallagher could also have a lasting impact on the broker industry
Advertisement

"It is not an easy job."

Dave Weisberger, chief executive of CoinRoutes, is talking about the chief legal position at Robinhood, the popular broker and app-maker with a Millennial focus. It's the way several sources familiar with Robinhood's business described the top legal job.

The company has experienced breakneck growth over the last two years. But it has also had its fair share of regulatory and legal hiccups stemming from platform outages, best-execution practices, and new product launches.

Last week, Robinhood raised an eye-popping $280 million Series F round. With less fanfare, Robinhood announced that its chief legal officer Anne Hoge – who joined the company in November 2019 – is set to leave at the end of the month. Hoge came from the technology world, previously holding top legal positions at NetApp and Yahoo.

The person stepping into the role – Dan Gallagher – brings experience from market structure world, suggesting that the firm might be shaking off its scrappy, move-fast-and-break-things mentality, according to industry experts.

Gallagher previously sat on Robinhood's board, having joined in November 2019. A former commissioner for the Securities and Exchange Commission, Gallagher is "very knowledgeable on the rules and the enforcement vectors taken by regulators, and will likely make some changes," Weisberger said.

On top of that, Gallagher is known as a keen political operator with close ties to Republicans in Congress as well as the leadership within the SEC.

Gallagher's story

Sworn in as a commissioner in 2011, Gallagher focused on capital markets and small business formation, according to his profile on the SEC's website.

Before joining the SEC, Gallagher was at the front lines of the financial crisis as a deputy director and co-acting director in the agency's Division of Trading Markets from 2008 to 2011. During that time, he represented the SEC in the liquidation of Lehman Brothers.

Later, as a commissioner, Gallagher contributed to the development of the JOBS Act, legislation meant to ease regulations around certain private sales.

He left the SEC in 2015 to enter the private sector and start his own consulting firm. Gallagher later drew on his public-sector experience to help pharmaceutical firm Mylan navigate its own regulatory issues. Mylan hired Gallagher in March 2017.

In 2019, the firm – under Gallagher's legal guidance – reached a $30 million settlement with the SEC, which had been investigating its accounting procedures around EpiPen, the emergency allergy shot.

The 3-year-long probe followed an earlier $465 settlement between the company and the Department of Justice and several other government agencies tied to alleged price-gouging of its EpiPen from $100 to more than $600, as reported by The New York Times.

Mylan did not admit wrongdoing, but the federal government claimed the company erroneously misclassified EpiPen as a generic drug, which allowed it to avoid paying certain rebates to the government.


© 2026 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.